Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| Merck & Co. (NYSE: MRK) | Delayed: 140.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $140.61 | 52 Week High | $65.46 | |||
| Open | $140.61 | 52 Week Low | $47.97 | |||
| Day High | $140.61 | P/E | 95.65 | |||
| Day Low | $140.61 | EPS | $1.47 | |||
| Volume | 2,660 | |||||
